132 related articles for article (PubMed ID: 9490197)
1. Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: towards the design of anticancer vaccines.
Kudryashov V; Kim HM; Ragupathi G; Danishefsky SJ; Livingston PO; Lloyd KO
Cancer Immunol Immunother; 1998 Feb; 45(6):281-6. PubMed ID: 9490197
[TBL] [Abstract][Full Text] [Related]
2. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice.
Kudryashov V; Glunz PW; Williams LJ; Hintermann S; Danishefsky SJ; Lloyd KO
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3264-9. PubMed ID: 11248067
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
[TBL] [Abstract][Full Text] [Related]
4. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
[TBL] [Abstract][Full Text] [Related]
5. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.
Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO
Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456
[TBL] [Abstract][Full Text] [Related]
6. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
7. Comparative immunological studies of tumor-associated Lewis X, Lewis Y, and KH-1 antigens.
Guo J; Jiang W; Li Q; Jaiswal M; Guo Z
Carbohydr Res; 2020 Jun; 492():107999. PubMed ID: 32272238
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
[TBL] [Abstract][Full Text] [Related]
10. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
[TBL] [Abstract][Full Text] [Related]
11. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization.
Spassova MK; Bornmann WG; Ragupathi G; Sukenick G; Livingston PO; Danishefsky SJ
J Org Chem; 2005 Apr; 70(9):3383-95. PubMed ID: 15844973
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a mouse monoclonal IgG3 antibody to the tumor-associated globo H structure produced by immunization with a synthetic glycoconjugate.
Kudryashov V; Ragupathi G; Kim IJ; Breimer ME; Danishefsky SJ; Livingston PO; Lloyd KO
Glycoconj J; 1998 Mar; 15(3):243-9. PubMed ID: 9579801
[TBL] [Abstract][Full Text] [Related]
14. Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants.
Kitamura K; Stockert E; Garin-Chesa P; Welt S; Lloyd KO; Armour KL; Wallace TP; Harris WJ; Carr FJ; Old LJ
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12957-61. PubMed ID: 7809154
[TBL] [Abstract][Full Text] [Related]
15. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm.
Ragupathi G; Koganty RR; Qiu D; Lloyd KO; Livingston PO
Glycoconj J; 1998 Mar; 15(3):217-21. PubMed ID: 9579798
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of Lewis Y Analogues and Their Protein Conjugates for Structure-Immunogenicity Relationship Studies of Lewis Y Antigen.
Li Q; Jiang W; Guo J; Jaiswal M; Guo Z
J Org Chem; 2019 Nov; 84(21):13232-13241. PubMed ID: 31565939
[TBL] [Abstract][Full Text] [Related]
17. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
18. Antigen coupled with Lewis-x trisaccharides elicits potent immune responses in mice.
Hsu SC; Tsai TH; Kawasaki H; Chen CH; Plunkett B; Lee RT; Lee YC; Huang SK
J Allergy Clin Immunol; 2007 Jun; 119(6):1522-8. PubMed ID: 17353042
[TBL] [Abstract][Full Text] [Related]
19. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
20. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
